阿斯利康：中国已成为其全球第二大市场，将第五次参加服贸会

Core Insights - AstraZeneca has been deeply rooted in China for over 30 years, emphasizing innovation as the core driver of medical advancement [3] - The company plans to invest $2.5 billion to establish its sixth global strategic R&D center in Beijing by 2025, following the upgrade of its Shanghai R&D center to a major strategic hub [3] - China has become AstraZeneca's second-largest market globally, with projected total revenue of $6.4 billion in 2024, accounting for 12% of the company's global income [5] R&D and Innovation - AstraZeneca's R&D pipeline in China includes over 200 projects, supported by a team of more than 1,000 researchers [3] - The company has formed partnerships with 14 local innovative enterprises since 2023, with a total collaboration amount exceeding $23 billion [3] - AstraZeneca aims to launch 20 global innovative drugs by 2030, having already introduced over 40 innovative medicines in various therapeutic areas [5] Social Responsibility and Environmental Initiatives - AstraZeneca is committed to green development and the green transformation of the industry, implementing measures to reduce environmental impact across all operations [5] - The company actively supports rural revitalization by enhancing access to quality medical resources in 400 cities and 2,800 counties, facilitating early screening and diagnosis [5] - AstraZeneca engages in public welfare activities, including free clinics, to address healthcare gaps in rural areas and improve the professional skills of local medical personnel [5][6] Future Outlook - AstraZeneca will continue to uphold its corporate social responsibility and explore innovations to contribute to the development of healthcare both in China and globally [6]